Listar por autor "Vera García, Ruth"
Mostrando ítems 1-17 de 17
-
Circulating low density neutrophils are associated with resistance to anti-PD1 immunotherapy in squamous head and neck cancer
Arrazubi, Virginia; Goñi Irigoyen, Saioa ; González Borja, Iranzu; Hernández García, Irene; Arasanz Esteban, Hugo; Pérez Sanz, Jairo; Bocanegra Gondán, Ana Isabel; Kochan, Grazyna; Escors Murugarren, David; Ruiz de Azúa, Yerani; Elizalde, Jesús María; Viúdez, Antonio; Vera García, Ruth (Wiley, 2023) Artículo / ArtikuluaBackground: Identification of predictive biomarkers to Immune checkpoint inhibitors (ICIs) in head and neck cancer (HNSCC) is an unmet need. Methods: This was a prospective observational study including 25 patients with ... -
Clinical landscape of LAG-3-targeted therapy
Chocarro, Luisa ; Blanco, Ester; Arasanz Esteban, Hugo; Fernández Rubio, Leticia; Bocanegra Gondán, Ana Isabel; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Fernández Hinojal, Gonzalo; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (Elsevier, 2022) Artículo / ArtikuluaLymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation ... -
Cutting-edge CAR engineering: beyond T cells
Chocarro, Luisa ; Blanco, Ester; Fernández Rubio, Leticia; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Piñeiro Hermida, Sergio; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2022) Artículo / ArtikuluaChimeric antigen receptor (CAR)-T adoptive cell therapy is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in haematological malignancies. However, it still lacks ... -
Cutting-edge: preclinical and clinical development of the first approved LAG-3 inhibitor
Chocarro, Luisa ; Bocanegra Gondán, Ana Isabel; Blanco, Ester; Fernández Rubio, Leticia; Arasanz Esteban, Hugo; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Piñeiro Hermida, Sergio; Vera García, Ruth; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2022) Artículo / ArtikuluaImmune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (LAG-3) is one of the most important ... -
Cytokines and lymphoid populations as potential biomarkers in locally and borderline pancreatic adenocarcinoma
González Borja, Iranzu; Viúdez, Antonio; Alors-Pérez, Emilia; Goñi Irigoyen, Saioa ; Amat Villegas, Irene ; Ghanem, Ismael; Pazo-Cid, Roberto; Feliu, Jaime; Alonso, Laura; López López, Carlos; Arrazubi, Virginia; Gallego, Javier; Pérez Sanz, Jairo; Hernández García, Irene; Vera García, Ruth; Castaño, Justo P.; Fernández Irigoyen, Joaquín (MDPI, 2022) Artículo / ArtikuluaDespite its relative low incidence, PDAC is one of the most aggressive and lethal types of cancer, being currently the seventh leading cause of cancer death worldwide, with a 5-year survival rate of 10.8%. Taking into ... -
Deciphering CHFR role in pancreatic ductal adenocarcinoma
González Borja, Iranzu; Alors-Pérez, Emilia; Amat Villegas, Irene ; Alonso, Laura; Viyuela-García, Cristina; Goñi Irigoyen, Saioa ; Reyes, José C.; Ceballos-Chávez, María; Hernández García, Irene; Sánchez-Frías, Marina E.; Santamaría, Enrique; Razquin, Socorro; Arjona Sánchez, Álvaro; Arrazubi, Virginia; Pérez Sanz, Jairo; Vera García, Ruth; Fernández Irigoyen, Joaquín ; Castaño, Justo P.; Viúdez, Antonio (Frontiers Media, 2021) Artículo / ArtikuluaCheckpoint with forkhead-associated and ring finger domains (CHFR) has been proposed as a predictive and prognosis biomarker for different tumor types, but its role in pancreatic ductal adenocarcinoma (PDAC) remains unknown. ... -
Immune profiling uncovers memory T-cell responses with a Th17 signature in cancer patients with previous SARS-CoV-2 infection followed by mRNA vaccination
Echaide Górriz, Míriam; Labiano, Ibone; Delgado, Marina; Fernández de Lascoiti, Ángela; Ochoa, Patricia; Garnica, Maider; Ramos, Pablo; Chocarro, Luisa ; Fernández Rubio, Leticia; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Blanco, Ester; Piñeiro Hermida, Sergio; Morente Sancho, Pilar; Vera García, Ruth; Alsina, María; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2022) Artículo / ArtikuluaIt is unclear whether patients with cancer present inherently impaired responses to COVID-19 and vaccination due to their treatments, neoplastic diseases or both. To address this question, immune profiling was performed ... -
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
Edwards, Carolyn J.; Sette, Angelica; Cox, Carl; Di Fiore, Barabara; Wyre, Chris; Sydoruk, Daniela; Yadin, David; Hayes, Philip; Stelter, Szymon; Bartlett, Phillip D.; Zuazo Ibarra, Miren ; García-Granda, María Jesús; Benedetti, Giovanni; Fiaska, Stratonik; Birkett, Neil R.; Teng, Yumin; Enever, Carrie; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Fernández, Gonzalo; Vera García, Ruth; Archer, Bethan; Osuch, Isabelle; Lewandowska, Martyna; Surani, Yasmin M.; Kochan, Grazyna; Escors Murugarren, David; Legg, James; Pierce, Andrew J. (Springer Nature, 2021) Artículo / ArtikuluaBackground: improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity ... -
A novel prognostic biomarker panel for early‐stage colon carcinoma
Azcue Sanromán, Pablo; Guerrero Setas, David; Encío Martínez, Ignacio ; Ibáñez Beroiz, B. ; Mercado Gutiérrez, María R.; Vera García, Ruth; Gómez Dorronsoro, María Luisa (MDPI, 2021) Artículo / ArtikuluaMolecular characterization of colorectal cancer has helped us understand better the biology of the disease. However, previous efforts have yet to provide significant clinical value in order to be integrated into clinical ... -
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies
Blanco, Ester; Silva-Pilipich, Noelia; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Procopio, Antonio; Ausín, Karina; Fernández Irigoyen, Joaquín ; Fernández Rubio, Leticia; Razquin, Nerea; Igea, Ana; Garnica, Maider; Echaide Górriz, Míriam; Arasanz Esteban, Hugo; Vera García, Ruth; Escors Murugarren, David; Smerdou, Cristian; Kochan, Grazyna (Springer Nature, 2024) Artículo / ArtikuluaBackground: Previous studies have shown that functional systemic immunity is required for the efficacy of PD-1/PD-L1 blockade immunotherapies in cancer. Hence, systemic reprogramming of immunosuppressive dysfunctional ... -
PD-L1 as a prognostic factor in early-stage colon carcinoma within the immunohistochemical molecular subtype classification
Azcue Sanromán, Pablo; Encío Martínez, Ignacio ; Guerrero Setas, David; Suarez Alecha, Javier; Galbete Jiménez, Arkaitz ; Mercado Gutiérrez, María R.; Vera García, Ruth; Gómez Dorronsoro, María Luisa (MDPI, 2021) Artículo / ArtikuluaColorectal cancer (CRC) is a very heterogeneous disease. Efforts to characterize and search for biomarkers for these patients are currently ongoing in the hope of establishing a more targeted therapeutic approach. The role ... -
PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer
Bocanegra Gondán, Ana Isabel; Fernandez Hinojal, Gonzalo; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Garcia-Granda, María Jesús; Hernandez, Carlos; Ibáñez-Vea, María ; Hernandez-Marin, Berta; Martinez-Aguillo, Maite; Lecumberri, María José; Fernández de Lascoiti, Ángela; Teijeira, Lucía; Morilla, Idoia; Vera García, Ruth; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2019) Artículo / ArtikuluaPD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade anticancer therapies, particularly for lung cancer. However, the reliability of this marker is still under debate. Moreover, ... -
PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity
Gato Cañas, María; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Ibáñez-Vea, María ; Lorenzo, Laura; Fernandez-Hinojal, Gonzalo; Vera García, Ruth; Smerdou, Cristian; Martisova, Eva; Arozarena Martinicorena, Imanol; Wellbrock, Claudia; Llopiz, Diana; Ruiz, Marta; Sarobe, Pablo; Breckpot, Karine; Kochan, Grazyna; Escors Murugarren, David (Elsevier, 2017) Artículo / ArtikuluaPDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation through prevention of PDL1-PD1 T cell inhibitory interactions. Here, we find that PDL1 cell-intrinsic signaling protects cancer ... -
Quality of life in Spanish advanced non-small-cell lung cancer patients: determinants of global QL and survival analyses
Arrarás, Juan Ignacio; Hernández, Berta; Martínez Aguillo, Maite; Cambra Contin, Koldo ; Rico, Mikel; Illarramendi, José Juan; Viúdez, Antonio; Ibáñez Beroiz, B. ; Zarandona, Uxue; Martínez, Enrique; Vera García, Ruth (Springer, 2016) Artículo / ArtikuluaPurpose: This paper studies the Quality of Life (QL) of Spanish advanced non-small-cell lung cancer (NSCLC) patients receiving platinum-doublet chemotherapy, compares our results with those from studies from other cultural ... -
Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
Escors Murugarren, David; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Blanco, Ester; Piñeiro Hermida, Sergio; Garnica, Maider; Fernández Rubio, Leticia; Vera García, Ruth; Arasanz Esteban, Hugo; Kochan, Grazyna (MDPI, 2022) Artículo / ArtikuluaPD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic ... -
Systemic CD4 immunity: a powerful clinical biomarker for PD-L1/PD-1 immunotherapy
Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Vera García, Ruth (EMBO Press, 2020) Artículo / ArtikuluaThe search for non-invasive systemic biomarkers of response to PD-L1/PD-1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful ... -
Understanding LAG-3 Signaling
Chocarro, Luisa ; Blanco, Ester; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Fernández Rubio, Leticia; Morente Sancho, Pilar; Fernández Hinojal, Gonzalo; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2021) Artículo / ArtikuluaLymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ...